Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 142Breast Neoplasms 97Lung Neoplasms 72Brain Neoplasms 67Glioblastoma 59Carcinoma, Non-Small-Cell Lung 54Glioma 52Pancreatic Neoplasms 39Neoplasms 39Neoplasm Metastasis 36Colorectal Neoplasms 31Carcinoma, Hepatocellular 30Lymphoma, Large B-Cell, Diffuse 27Carcinoma, Renal Cell 27Multiple Myeloma 26Squamous Cell Carcinoma of Head and Neck 25Rectal Neoplasms 21Melanoma 21Ovarian Neoplasms 20Astrocytoma 20Urinary Bladder Neoplasms 18Lymphoma, Follicular 18Uterine Cervical Neoplasms 17Colonic Neoplasms 17Head and Neck Neoplasms 16Lymphoma 15Esophageal Neoplasms 15Sarcoma 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell 14

Interventions

pembrolizumab 1enfortumab vedotin 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urachal adenocarcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Emory University

Phase 2 Recruiting
25 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡